The FDA has approved once-daily Luvox CR (fluvoxamine maleate extended-release capsules, from Jazz) for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD). This approval is supported by three clinical trials involving approximately 600 patients that showed significant improvement in SAD and OCD symptoms in the Luvox CR-treated group compared to placebo. Luvox CR will be available in 100mg and 150mg dose strengths and is expected to be available in March 2008.

For more information call (650) 496-3777 or visit www.jazzpharmaceuticals.com.